サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1791544

二特異性抗体の世界市場

Bispecific Antibodies

出版日
ページ情報
英文 104 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.90円
二特異性抗体の世界市場
出版日: 2025年08月15日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 104 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

二特異性抗体の世界市場は2030年までに1,257億米ドルに達する見込み

2024年に148億米ドルと推定される二特異性抗体の世界市場は、2024年から2030年にかけてCAGR 42.9%で成長し、2030年には1,257億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるがんは、CAGR 48.9%を記録し、分析期間終了時には714億米ドルに達すると予測されます。炎症性・自己免疫疾患分野の成長率は、分析期間のCAGRで39.8％と推定されます。

米国市場は推定39億米ドル、中国はCAGR40.2％で成長予測

米国の二特異性抗体市場は2024年に39億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに182億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは40.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ39.7%と36.1%と予測されています。欧州では、ドイツがCAGR 28.4%で成長すると予測されています。

世界の二特異性抗体市場- 主要動向と促進要因のまとめ

二特異性抗体が標的治療の未来を変える理由とは？

二特異性抗体（BsAbs）は、2つの異なる抗原またはエピトープに同時に結合する能力を提供することにより、免疫療法と精密医療の分野に革命をもたらしています。単一の抗原を標的とする従来のモノクローナル抗体（mAbs）とは異なり、二特異性抗体は一度に複数の生物学的経路に関与することで治療効果を高めます。このユニークな能力により、BsAbsは、特に腫瘍学、自己免疫疾患、感染症において、画期的な治療法として位置づけられています。免疫細胞と腫瘍細胞を橋渡しし、二重のシグナル伝達経路を遮断し、薬物の特異性を向上させる能力により、次世代の二特異性抗体療法の研究開発が急増しています。

がん、特に血液悪性腫瘍や固形がんの有病率の増加は、二重特異性抗体市場の主要な促進要因です。B細胞性急性リンパ芽球性白血病（B-ALL）に対するブリナツモマブ（blinatumomab）のような二重特異性T細胞エンゲイジャー（BiTE）の薬事承認は、BsAbsの臨床的可能性を検証し、パイプライン開発への投資の増加につながりました。さらに、タンパク質工学、Fc修飾、新規二重特異性フォーマットの進歩により、これらの治療薬の安定性、製造可能性、薬物動態が向上しています。より少ない副作用でより高い有効性を提供する標的治療への需要が高まる中、二特異性抗体は次世代の治療クラスとして急速に支持を集めています。

技術革新はどのように二重特異性抗体開発を進めているのか？

抗体工学、タンパク質設計、薬物結合における重要なブレークスルーが、二特異性抗体の急速な進化を促し、より効果的で汎用性の高い治療ソリューションの開発を可能にしています。最も重要な進歩の一つは、ノブ・イン・ホール（KIH）技術、デュアル・バリアブル・ドメイン・イムノグロブリン（DVD-Ig）、ナノボディ・ベースのBsAbsなど、新しい二重特異性抗体フォーマットの出現です。これらのフォーマットは安定性を向上させ、免疫原性を最小化し、効率的な大量製造を可能にします。さらに、Fcエンジニアリング技術を取り入れることで、二特異性抗体の半減期とバイオアベイラビリティが向上し、初期のBsAb開発における主要課題のひとつに取り組んでいます。

もう一つの画期的な技術革新は、三特異性および多特異性抗体プラットフォームの開発であり、これは3つ以上の異なるエピトープを標的とすることにより、BsAbsの治療効果を拡大するものです。さらに、AIによる抗体探索とin silicoモデリングは、最適な二重特異性構築物の同定を加速し、開発期間を短縮し、前臨床試験や臨床試験の成功率を向上させています。二特異性抗体とCAR-T療法やNK細胞療法などの細胞療法アプローチとの統合も、腫瘍学における併用治療の新たな機会を生み出しています。二重特異性抗体製剤の改良と臨床転帰の改善に関する研究が進むにつれて、こうした技術的進歩が精密医療の未来を形作りつつあります。

二特異性抗体産業の成長を牽引する市場動向は？

免疫療法と標的生物製剤の採用が増加していることは、二特異性抗体市場の成長を推進している最も重要な動向の一つです。免疫チェックポイント阻害剤やCAR-T療法の成功により、がん治療の有望な代替・補完アプローチとして二特異性抗体に焦点が移っています。免疫チェックポイント阻害剤や化学療法と並行してBsAbsを使用する併用療法の台頭は、臨床応用をさらに拡大させています。さらに、個別化医療へのシフトが、特定の患者集団や腫瘍微小環境に合わせた二特異性抗体の需要を促進しています。

市場を形成するもう一つの大きな動向は、二特異性抗体のがん領域以外への拡大です。がん治療が依然として主要な用途である一方、自己免疫疾患、感染症、神経変性疾患へのBsAbsの応用がますます検討されています。極めて特異的に免疫反応を調節できることから、二特異性抗体は関節リウマチ、ループス、HIVなどの治療において魅力的な選択肢となっています。さらに、バイオ医薬品業界では、二重特異性抗体の生産と商業化を加速するために、バイオテクノロジー企業、学術研究機関、開発・製造受託機関（CDMO）の間で共同研究が増加しています。規制当局が革新的な生物製剤の承認経路を合理化するにつれて、BsAbs市場は大きく拡大する態勢を整えています。

二重特異性抗体市場の将来を形作る主な成長促進要因は何か？

二重特異性抗体市場の成長は、がん罹患率の上昇、抗体工学の進歩、次世代生物製剤へのバイオファーマ投資の増加など、いくつかの重要な要因によってもたらされます。最も重要な要因の一つは、血液悪性腫瘍や固形がんに対する効果的な治療に対するニーズの高まりです。二重特異性T細胞エンゲイジャー（BiTE）やデュアルターゲットの免疫チェックポイント阻害剤は、がん細胞を攻撃する免疫細胞のリクルートにおいて優れた有効性を示しており、臨床試験中のBsAb候補の強力なパイプラインにつながっています。

市場を形成するもう一つの重要な要因は、バイオ医薬品の研究開発投資の継続的な拡大です。大手製薬会社やバイオテクノロジー企業が二重特異性抗体開発に多額のリソースを割いているため、臨床段階にあるBsAb候補の数は急速に増加しています。さらに、シングルユース・バイオリアクターや連続処理などのバイオ製造技術の進歩により、生産効率の向上とコスト削減が進み、BsAbsはより商業的に実行可能なものとなっています。二重特異性抗体薬物複合体（BsADC）のような次世代ドラッグデリバリー・システムの出現も、標的治療の技術革新を促進すると予想されます。バイオファーマ各社が生物学的製剤開発の限界に挑み続ける中、二特異性抗体は精密医療の次の波の礎となり、広範な疾患に対する新たな治療選択肢を提供することになると思われます。

セグメント

適応症タイプ（がん、炎症性疾患および自己免疫疾患、その他の適応症タイプ）

調査対象企業の例

  • Akeso, Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • Genmab A/S
  • GSK Plc
  • Immunocore
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • OncXerna Therapeutics
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Sino Biological, Inc.
  • Taisho Pharmaceutical Co., Ltd.
  • Zymeworks, Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP29616

Global Bispecific Antibodies Market to Reach US$125.7 Billion by 2030

The global market for Bispecific Antibodies estimated at US$14.8 Billion in the year 2024, is expected to reach US$125.7 Billion by 2030, growing at a CAGR of 42.9% over the analysis period 2024-2030. Cancer, one of the segments analyzed in the report, is expected to record a 48.9% CAGR and reach US$71.4 Billion by the end of the analysis period. Growth in the Inflammatory & Autoimmune Disorder segment is estimated at 39.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.9 Billion While China is Forecast to Grow at 40.2% CAGR

The Bispecific Antibodies market in the U.S. is estimated at US$3.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$18.2 Billion by the year 2030 trailing a CAGR of 40.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 39.7% and 36.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 28.4% CAGR.

Global Bispecific Antibodies Market - Key Trends & Drivers Summarized

Why Are Bispecific Antibodies Transforming the Future of Targeted Therapies?

Bispecific antibodies (BsAbs) are revolutionizing the field of immunotherapy and precision medicine by offering the ability to simultaneously bind to two different antigens or epitopes. Unlike conventional monoclonal antibodies (mAbs), which target a single antigen, bispecific antibodies enhance therapeutic efficacy by engaging multiple biological pathways at once. This unique capability has positioned BsAbs as a game-changing treatment modality, particularly in oncology, autoimmune disorders, and infectious diseases. The ability to bridge immune cells to tumor cells, block dual signaling pathways, and improve drug specificity has led to a surge in research and development for next-generation bispecific antibody therapies.

The growing prevalence of cancer, particularly hematologic malignancies and solid tumors, is a primary driver of the bispecific antibody market. Regulatory approvals of bispecific T-cell engagers (BiTEs) such as blinatumomab for B-cell acute lymphoblastic leukemia (B-ALL) have validated the clinical potential of BsAbs, leading to increased investments in pipeline development. Additionally, advances in protein engineering, Fc modifications, and novel bispecific formats have enhanced the stability, manufacturability, and pharmacokinetics of these therapies. With the rising demand for targeted treatments that offer higher efficacy with fewer side effects, bispecific antibodies are rapidly gaining traction as a next-generation therapeutic class.

How Are Technological Innovations Advancing Bispecific Antibody Development?

Significant breakthroughs in antibody engineering, protein design, and drug conjugation are driving the rapid evolution of bispecific antibodies, enabling the development of more effective and versatile therapeutic solutions. One of the most critical advancements is the emergence of novel bispecific antibody formats, including knob-into-hole (KIH) technology, dual-variable domain immunoglobulins (DVD-Ig), and nanobody-based BsAbs. These formats improve stability, minimize immunogenicity, and allow for efficient large-scale manufacturing. Additionally, the incorporation of Fc-engineering techniques has enhanced the half-life and bioavailability of bispecific antibodies, addressing one of the major challenges in early BsAb development.

Another groundbreaking innovation is the development of trispecific and multi-specific antibody platforms, which extend the therapeutic benefits of BsAbs by targeting three or more distinct epitopes. Additionally, AI-driven antibody discovery and in silico modeling are accelerating the identification of optimal bispecific constructs, reducing development timelines and improving success rates in preclinical and clinical trials. The integration of bispecific antibodies with cell therapy approaches, such as CAR-T and NK-cell therapy, is also creating new opportunities for combination treatments in oncology. As research continues to refine bispecific antibody formats and improve clinical outcomes, these technological advancements are shaping the future of precision medicine.

Which Market Trends Are Driving Growth in the Bispecific Antibody Industry?

The increasing adoption of immunotherapy and targeted biologics is one of the most significant trends propelling the growth of the bispecific antibody market. With the success of immune checkpoint inhibitors and CAR-T therapies, the focus has shifted toward bispecific antibodies as a promising alternative or complementary approach to cancer treatment. The rise of combination therapies, where BsAbs are used alongside immune checkpoint inhibitors or chemotherapies, is further expanding their clinical applications. Additionally, the shift toward personalized medicine is driving demand for bispecific antibodies tailored to specific patient populations and tumor microenvironments.

Another major trend shaping the market is the expansion of bispecific antibodies beyond oncology. While cancer treatment remains the dominant application, BsAbs are increasingly being explored for autoimmune diseases, infectious diseases, and neurodegenerative disorders. The ability to modulate immune responses in a highly specific manner has made bispecific antibodies an attractive option for treating conditions such as rheumatoid arthritis, lupus, and HIV. Additionally, the biopharmaceutical industry is witnessing increased collaborations between biotech firms, academic research institutions, and contract development and manufacturing organizations (CDMOs) to accelerate bispecific antibody production and commercialization. As regulatory agencies streamline approval pathways for innovative biologics, the market for BsAbs is poised for significant expansion.

What Are the Key Growth Drivers Shaping the Future of the Bispecific Antibody Market?

The growth in the bispecific antibody market is driven by several key factors, including rising cancer prevalence, advancements in antibody engineering, and increasing biopharma investments in next-generation biologics. One of the most significant drivers is the growing need for effective treatments for hematologic malignancies and solid tumors. Bispecific T-cell engagers (BiTEs) and dual-targeting immune checkpoint inhibitors have demonstrated superior efficacy in recruiting immune cells to attack cancer cells, leading to a strong pipeline of BsAb candidates in clinical trials.

Another crucial driver shaping the market is the continuous expansion of biopharmaceutical R&D investments. With major pharmaceutical companies and biotech firms allocating substantial resources to bispecific antibody development, the number of clinical-stage BsAb candidates is rapidly increasing. Additionally, advancements in biomanufacturing techniques, including single-use bioreactors and continuous processing, are improving production efficiency and reducing costs, making BsAbs more commercially viable. The emergence of next-generation drug delivery systems, such as bispecific antibody-drug conjugates (BsADCs), is also expected to drive innovation in targeted therapies. As biopharma companies continue to push the boundaries of biologic drug development, bispecific antibodies are set to become a cornerstone of the next wave of precision medicine, offering novel treatment options for a wide range of diseases.

SCOPE OF STUDY:

The report analyzes the Bispecific Antibodies market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication Type (Cancer, Inflammatory and Autoimmune Disorder, Other Indication Types)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 36 Featured) -

  • Akeso, Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • Genmab A/S
  • GSK Plc
  • Immunocore
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • OncXerna Therapeutics
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Sino Biological, Inc.
  • Taisho Pharmaceutical Co., Ltd.
  • Zymeworks, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Bispecific Antibodies - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Next-Generation Immunotherapies Throws the Spotlight on Bispecific Antibodies as Game-Changing Modalities
    • Growing Oncology Pipeline Drives Accelerated Adoption of Bispecific Antibody Platforms in Targeted Cancer Treatment
    • Ability to Simultaneously Bind Two Targets Strengthens the Business Case for Bispecifics in Complex Disease Management
    • Shift Toward T-cell Engagers and Dual-Antigen Targeting Expands Addressable Market Opportunity in Hematologic and Solid Tumors
    • Clinical Limitations of Monoclonal Antibodies Spur Innovation in Bispecific Therapeutic Strategies
    • Technological Advancements in Antibody Engineering Propel Development of Highly Specific and Stable Bispecific Constructs
    • Big Pharma and Biotech Partnerships Accelerate the Commercialization Pipeline for Bispecific Antibody Therapeutics
    • Increased Investment in CDMO and CMO Capabilities Supports Scalable Manufacturing of Complex Bispecific Formats
    • Expansion of Bispecific Applications Beyond Oncology Drives Interest in Autoimmune, Infectious, and Inflammatory Diseases
    • Rising Clinical Success and Approvals of First-Generation Bispecifics Pave the Way for Competitive Market Differentiation
    • Growing Focus on Subcutaneous and Self-Administered Delivery Forms Enhances Patient Convenience and Market Uptake
    • Emerging Bispecific Antibody Formats Spur Innovation Across Development Pipelines
    • Advances in Protein Expression Systems and Purification Technologies Improve Production Yields and Commercial Viability
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Bispecific Antibodies Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Bispecific Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Bispecific Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Inflammatory & Autoimmune Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Inflammatory & Autoimmune Disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Other Indication Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Other Indication Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Bispecific Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 10: USA Recent Past, Current & Future Analysis for Bispecific Antibodies by Indication Type - Cancer, Inflammatory & Autoimmune Disorder and Other Indication Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 11: USA 6-Year Perspective for Bispecific Antibodies by Indication Type - Percentage Breakdown of Value Sales for Cancer, Inflammatory & Autoimmune Disorder and Other Indication Types for the Years 2025 & 2030
  • CANADA
    • TABLE 12: Canada Recent Past, Current & Future Analysis for Bispecific Antibodies by Indication Type - Cancer, Inflammatory & Autoimmune Disorder and Other Indication Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 13: Canada 6-Year Perspective for Bispecific Antibodies by Indication Type - Percentage Breakdown of Value Sales for Cancer, Inflammatory & Autoimmune Disorder and Other Indication Types for the Years 2025 & 2030
  • JAPAN
    • Bispecific Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 14: Japan Recent Past, Current & Future Analysis for Bispecific Antibodies by Indication Type - Cancer, Inflammatory & Autoimmune Disorder and Other Indication Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 15: Japan 6-Year Perspective for Bispecific Antibodies by Indication Type - Percentage Breakdown of Value Sales for Cancer, Inflammatory & Autoimmune Disorder and Other Indication Types for the Years 2025 & 2030
  • CHINA
    • Bispecific Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 16: China Recent Past, Current & Future Analysis for Bispecific Antibodies by Indication Type - Cancer, Inflammatory & Autoimmune Disorder and Other Indication Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 17: China 6-Year Perspective for Bispecific Antibodies by Indication Type - Percentage Breakdown of Value Sales for Cancer, Inflammatory & Autoimmune Disorder and Other Indication Types for the Years 2025 & 2030
  • EUROPE
    • Bispecific Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 18: Europe Recent Past, Current & Future Analysis for Bispecific Antibodies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: Europe 6-Year Perspective for Bispecific Antibodies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 20: Europe Recent Past, Current & Future Analysis for Bispecific Antibodies by Indication Type - Cancer, Inflammatory & Autoimmune Disorder and Other Indication Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Europe 6-Year Perspective for Bispecific Antibodies by Indication Type - Percentage Breakdown of Value Sales for Cancer, Inflammatory & Autoimmune Disorder and Other Indication Types for the Years 2025 & 2030
  • FRANCE
    • Bispecific Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 22: France Recent Past, Current & Future Analysis for Bispecific Antibodies by Indication Type - Cancer, Inflammatory & Autoimmune Disorder and Other Indication Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 23: France 6-Year Perspective for Bispecific Antibodies by Indication Type - Percentage Breakdown of Value Sales for Cancer, Inflammatory & Autoimmune Disorder and Other Indication Types for the Years 2025 & 2030
  • GERMANY
    • Bispecific Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 24: Germany Recent Past, Current & Future Analysis for Bispecific Antibodies by Indication Type - Cancer, Inflammatory & Autoimmune Disorder and Other Indication Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Germany 6-Year Perspective for Bispecific Antibodies by Indication Type - Percentage Breakdown of Value Sales for Cancer, Inflammatory & Autoimmune Disorder and Other Indication Types for the Years 2025 & 2030
  • ITALY
    • TABLE 26: Italy Recent Past, Current & Future Analysis for Bispecific Antibodies by Indication Type - Cancer, Inflammatory & Autoimmune Disorder and Other Indication Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Italy 6-Year Perspective for Bispecific Antibodies by Indication Type - Percentage Breakdown of Value Sales for Cancer, Inflammatory & Autoimmune Disorder and Other Indication Types for the Years 2025 & 2030
  • UNITED KINGDOM
    • Bispecific Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 28: UK Recent Past, Current & Future Analysis for Bispecific Antibodies by Indication Type - Cancer, Inflammatory & Autoimmune Disorder and Other Indication Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: UK 6-Year Perspective for Bispecific Antibodies by Indication Type - Percentage Breakdown of Value Sales for Cancer, Inflammatory & Autoimmune Disorder and Other Indication Types for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 30: Rest of Europe Recent Past, Current & Future Analysis for Bispecific Antibodies by Indication Type - Cancer, Inflammatory & Autoimmune Disorder and Other Indication Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Rest of Europe 6-Year Perspective for Bispecific Antibodies by Indication Type - Percentage Breakdown of Value Sales for Cancer, Inflammatory & Autoimmune Disorder and Other Indication Types for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Bispecific Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 32: Asia-Pacific Recent Past, Current & Future Analysis for Bispecific Antibodies by Indication Type - Cancer, Inflammatory & Autoimmune Disorder and Other Indication Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Asia-Pacific 6-Year Perspective for Bispecific Antibodies by Indication Type - Percentage Breakdown of Value Sales for Cancer, Inflammatory & Autoimmune Disorder and Other Indication Types for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 34: Rest of World Recent Past, Current & Future Analysis for Bispecific Antibodies by Indication Type - Cancer, Inflammatory & Autoimmune Disorder and Other Indication Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Rest of World 6-Year Perspective for Bispecific Antibodies by Indication Type - Percentage Breakdown of Value Sales for Cancer, Inflammatory & Autoimmune Disorder and Other Indication Types for the Years 2025 & 2030

IV. COMPETITION